Fusion and Cyteir refocus pipelines; Nona Biosciences collaborating with PharmaEssentia
Several biotechs are looking to make changes to their pipelines as the quarter has drawn to a close.
Massachusetts-based Cyteir said Wednesday it is going to focus on CYT-0851, which is designed to be used in combination with capecitabine as a treatment for advanced ovarian cancer. For its preclinical DNA polymerase theta inhibitor program, it plans to out-license the program, the company announced in its Q1 report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.